IDH1 and glioblastoma: We report that MACC1 transcripts are detectable and enhanced in the blood of GBM patients, cluster together with other prognostic markers of clinical importance, and are associated with patients’ prognosis in conjunction with the IDH1 mutation status and the treatment regimen.